Sandoz Shares Decline on US Generic Drug Tariff Threat

Shares of Sandoz (SDZ) fell more than 3% after the U.S. announced plans to impose significant future tariffs on imported generic drugs, a move that directly targets the business model of the Swiss pharmaceutical giant.

Tariff Impact on Generics Sector

The proposed U.S. policy would introduce a 100% import tariff on generic drugs starting in August 2028, according to reports. That rate would escalate to 200% by August 2029 for companies that fail to move manufacturing operations to the United States.

As one of the world's largest generics and biosimilars companies, Sandoz is highly exposed to this policy due to its extensive international manufacturing network and its significant presence in the U.S. market. The news sent the stock down 3.2% to CHF 64.40, hitting a session low of CHF 63.78 and leaving it roughly 14% below its 52-week high.

Analyst Caution and Upcoming Earnings

Ad

The tariff threat compounds an already cautious analyst environment surrounding the stock. Earlier in July, Jefferies trimmed its price target on Sandoz, while Deutsche Bank had previously lowered its target to CHF 65 with a 'Hold' rating.

With Sandoz scheduled to release its Q2 2026 earnings on August 5, investors appear hesitant to add risk. The market will be looking for management to address the potential impact of the tariffs on the company's future financial guidance.

Broader Market Context

The sell-off in Sandoz shares came amid a wider risk-off tone in markets, with the S&P 500 and Nasdaq also declining on the day. Other pharmaceutical companies with substantial generic drug exposure face similar headwinds from the policy announcement, while firms focused on patented, branded medicines may be more insulated.